

Biological and Immunological Potencies of Lutropin (LH) Studies Using Different Standard Preparations

Hormone and Metabolic Research

14, 39-45

DOI: 10.1055/s-2007-1018915

Citation Report

#	ARTICLE	IF	CITATIONS
1	MICROHETEROGENEITY OF LUTEINIZING HORMONE IN PITUITARY GLANDS FROM WOMEN OF PRE- AND POSTMENOPAUSAL AGE. <i>Clinical Endocrinology</i> , 1983, 19, 355-363.	2.4	55
2	Polymorphism of human pituitary lutropin (LH). <i>FEBS Letters</i> , 1983, 159, 93-96.	2.8	23
3	Effects of acute stimulation with luteinizing hormone-releasing hormone (LRH) on biologically active and immunoreactive serum luteinizing hormone (LH) in pubertal boys. <i>European Journal of Endocrinology</i> , 1984, 107, 289-294.	3.7	12
4	Differences in the Ratio of Bioactive to Immunoreactive Serum Luteinizing Hormone during Vasomotor Flushes and Hormonal Therapy in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 58, 925-929.	3.6	26
5	Varying Bioactive to Immunoactive Ratios of the Human Chorionic Gonadotropin-Like Substance Present in Normal Human Tissues*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 58, 170-175.	3.6	18
6	Desensitization of the cAMP system in mouse Leydig cells by hCG, cholera toxin, dibutyryl cAMP and cAMP: localization of the "lesion" to the guanine nucleotide regulatory protein-adenylate cyclase complex. <i>Molecular and Cellular Endocrinology</i> , 1984, 34, 67-80.	3.2	48
7	Effects of acute stimulation with gonadotropin releasing hormone (GnRH) on biologically active serum luteinizing hormone (LH) in elderly men. <i>Journal of Endocrinological Investigation</i> , 1984, 7, 589-595.	3.3	13
8	Polymorphism of human pituitary lutropin (LH). <i>FEBS Letters</i> , 1984, 169, 21-24.	2.8	20
9	The Changing Ratio of Bioactive to Immunoreactive Luteinizing Hormone (LH) through Puberty Principally Reflects Changing LH Radioimmunoassay Dose-Response Characteristics*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1985, 61, 508-513.	3.6	39
10	Desensitization of Mouse Leydig Cells in Vivo: Evidence for the Depletion of Cellular Cholesterol1. <i>Biology of Reproduction</i> , 1985, 33, 335-345.	2.7	21
11	LOSS OF LUTEINIZING HORMONE BIOACTIVITY IN PATIENTS WITH PROSTATIC CANCER TREATED WITH AN LHRH AGONIST AND A PURE ANTIANDROGEN. <i>Clinical Endocrinology</i> , 1986, 24, 21-30.	2.4	33
12	BIOACTIVE LUTEINIZING HORMONE IN PLASMA OF URAEMIC MEN AND MEN WITH PRIMARY TESTICULAR DAMAGE. <i>Clinical Endocrinology</i> , 1986, 24, 259-266.	2.4	14
13	Characteristics of Radioimmunoassays for the $\hat{1}$ - and $\hat{2}$ -Subunits of Human Luteinizing Hormone. <i>Journal of Immunoassay</i> , 1987, 8, 97-114.	0.3	1
14	Luteinizing hormone bioactivity in human menopausal gonadotropin/human chorionic gonadotropin-induced cycles **Presented at the Thirty-Third Annual Meeting of the Society of Gynecologic Investigation, Toronto, Ontario, Canada, March 19 to 22, 1986.. <i>Fertility and Sterility</i> , 1987, 47, 238-243.	1.0	5
15	THE ROLE OF MODERN BIOASSAYS IN CLINICAL ENDOCRINOLOGY. <i>Clinical Endocrinology</i> , 1987, 27, 259-278.	2.4	27
16	OVARIAN SUPPRESSION IN POLYCYSTIC OVARIAN DISEASE DURING 6 MONTH ADMINISTRATION OF A LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) AGONIST. <i>Clinical Endocrinology</i> , 1987, 27, 703-713.	2.4	36
17	CHANGES IN THE QUALITATIVE AND QUANTITATIVE SECRETION OF LUTEINIZING HORMONE (LH) FOLLOWING ORCHIDECTOMY IN MAN. <i>Clinical Endocrinology</i> , 1988, 29, 189-194.	2.4	14
18	ACUTE PITUITARY-OVARIAN RESPONSE DURING CHRONIC LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTRATION IN POLYCYSTIC OVARIAN SYNDROME. <i>Clinical Endocrinology</i> , 1988, 29, 403-410.	2.4	7

#	ARTICLE	IF	CITATIONS
19	Changes in the bioactivity to immunoreactivity ratio of circulating luteinizing hormone in impotent men treated with testosterone undecanoate. <i>European Journal of Endocrinology</i> , 1989, 120, 284-288.	3.7	9
20	Pulsatile Bioactive Luteinizing Hormone Secretion in Men with Chronic Renal Failure and following Renal Transplantation. <i>Nephron</i> , 1990, 56, 66-72.	1.8	22
21	Gonadotrophin releasing hormone agonist suppressive treatment of ovarian function decreases serum LH- β and bioactive LH but maintains elevated levels of LH- α . <i>Clinical Endocrinology</i> , 1991, 34, 191-196.	2.4	10
22	Bioactive gonadotrophin secretion in man. <i>Clinical Endocrinology</i> , 1991, 35, 193-206.	2.4	24
23	Polyunsaturated fats enhance peripheral glucose utilization in rats.. <i>Journal of the American College of Nutrition</i> , 1991, 10, 340-345.	1.8	32
24	Less acidic forms of luteinizing hormone are associated with lower testosterone secretion in men on haemodialysis treatment. <i>Clinical Endocrinology</i> , 1994, 41, 65-73.	2.4	44
25	FSH bioactivity in commercial preparations of gonadotropins. <i>Theriogenology</i> , 1998, 49, 1031-1037.	2.1	18
26	Inhibitory effect of plasma obtained from hypophysectomized and control women on the assay of bioactive luteinizing hormone. <i>Human Reproduction</i> , 1999, 14, 312-317.	0.9	3
27	Bioactivity of Luteinizing Hormone during Normal Puberty in Girls and Boys. <i>Hormone Research in Paediatrics</i> , 1999, 51, 230-237.	1.8	9
28	Statistical Correction for Non-parallelism in a Urinary Enzyme Immunoassay. <i>Journal of Immunoassay and Immunochemistry</i> , 2004, 25, 259-278.	1.1	35
29	Comparison of the Biological and Immunological Activities of Serum Luteinizing Hormone and Follicle Stimulating Hormone in Infertile Males. <i>Andrologia</i> , 2009, 16, 559-567.	2.1	4
30	A Rise in the Biologically Active LH: Immunologically Active LH (B/I) Ratio during the Normal Luteal Phase. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1989, 15, 299-305.	0.0	1